Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
|Videos|September 28, 2020
Stress Reactions to COVID-19
Author(s)Victor Schwartz, MD
This video examines the differences between typical, non-pathological reactions to the stress induced by the COVID-19 pandemic and psychopathology (or mental illness).
Advertisement
The clinical and policy ramifications of this confusion of categories is also explored in addition to explaining the value and importance of affirming the real-even if painful-emotional experiences of those impacted by the pandemic.
Dr Schwartz is Clinical Associate Professor of Psychiatry, NYU School of Medicine and CEO of Mind Strategies.
Advertisement
Related to this article
How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
Male athletes with anorexia often go unnoticed as “discipline”; learn red flags, sport-specific risks, health consequences, and treatment steps for earlier diagnosis.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
A psychiatric NP shares mentorship lessons, training fixes, and her Psych NP Boot Camp—plus practical tips to close prescriber gaps and improve team-based care.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Advertisement
Advertisement